Adagene Inc
NASDAQ:ADAG

Watchlist Manager
Adagene Inc Logo
Adagene Inc
NASDAQ:ADAG
Watchlist
Price: 2.22 USD -2.2% Market Closed
Market Cap: 98.3m USD
Have any thoughts about
Adagene Inc?
Write Note

Adagene Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Adagene Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Adagene Inc
NASDAQ:ADAG
Revenue
$18.1m
CAGR 3-Years
196%
CAGR 5-Years
64%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Revenue
ÂĄ17.4B
CAGR 3-Years
102%
CAGR 5-Years
68%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Revenue
ÂĄ4.5B
CAGR 3-Years
N/A
CAGR 5-Years
337%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Revenue
ÂĄ5.5B
CAGR 3-Years
33%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Revenue
ÂĄ8.3B
CAGR 3-Years
37%
CAGR 5-Years
31%
CAGR 10-Years
27%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Revenue
ÂĄ36.4B
CAGR 3-Years
12%
CAGR 5-Years
31%
CAGR 10-Years
47%
No Stocks Found

Adagene Inc
Glance View

Market Cap
98.3m USD
Industry
Biotechnology

Adagene, Inc. engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

ADAG Intrinsic Value
0.92 USD
Overvaluation 59%
Intrinsic Value
Price

See Also

What is Adagene Inc's Revenue?
Revenue
18.1m USD

Based on the financial report for Dec 31, 2023, Adagene Inc's Revenue amounts to 18.1m USD.

What is Adagene Inc's Revenue growth rate?
Revenue CAGR 5Y
64%

Over the last year, the Revenue growth was 95%. The average annual Revenue growth rates for Adagene Inc have been 196% over the past three years , 64% over the past five years .

Back to Top